deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02485249

Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema

Sponsor: Eyegate Pharmaceuticals, Inc.

Conditions Macular Edema
Updated 6 times since 2017 Last updated: Aug 1, 2016 Started: Jul 31, 2015 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow enrollment

A PHASE1/PHASE2 clinical study on Macular Edema, this trial is terminated or withdrawn. The trial is conducted by Eyegate Pharmaceuticals, Inc. and has accumulated 6 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

Show 1 earlier version
  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1_PHASE2

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eyegate Pharmaceuticals, Inc.
Data source: Eyegate Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations